Abstract:Recently, we have reported the chemical properties of some jellyfish proteinaceous toxins. These were the first chemical characterizations of jellyfish protein toxins to be reported. The isolation of the proteinaceous toxins in their active forms was the key step in the studies. We isolated the toxins from three box jellyfish (Cubozoa) species [Carybdea rastoni (C. rastoni), Carybdea alata (C. alata), and Chiropsalmus quadrigatus (C. quadrigatus)]. These toxins showed lethal toxicity to crustaceans and hemolyt… Show more
“…Although the rat studies suggest that Type I toxins elicit more potent cardiovascular effects in vertebrates than Type II toxins, some experimental evidence suggests that the Type II toxins elicit more potent effects in invertebrates. For example, in earlier studies on crustaceans, researchers found that the LD 50 values of Type II toxins CaTX-A and CrTX-A (5-25 g kg Ϫ1 ) were lower than the Type I toxin CqTX-A (80 g kg Ϫ1 ) (43). Comparative studies on the invertebrate toxicity of purified CfTX-1/2 and CfTX- A/B have yet to be published, but they would undoubtedly provide important information on the target specificity of the two toxin types.…”
Background: Box jellyfish produce a unique family of toxic venom proteins. Results: The toxins are structurally similar, yet two subgroups confer different cytolytic activities in red blood cells and cardiovascular effects in rats. Conclusion: Diversification within the toxin family may influence toxin function/specificity. Significance: Characterization of the toxins provides new insight into their potential roles in human envenoming.
“…Although the rat studies suggest that Type I toxins elicit more potent cardiovascular effects in vertebrates than Type II toxins, some experimental evidence suggests that the Type II toxins elicit more potent effects in invertebrates. For example, in earlier studies on crustaceans, researchers found that the LD 50 values of Type II toxins CaTX-A and CrTX-A (5-25 g kg Ϫ1 ) were lower than the Type I toxin CqTX-A (80 g kg Ϫ1 ) (43). Comparative studies on the invertebrate toxicity of purified CfTX-1/2 and CfTX- A/B have yet to be published, but they would undoubtedly provide important information on the target specificity of the two toxin types.…”
Background: Box jellyfish produce a unique family of toxic venom proteins. Results: The toxins are structurally similar, yet two subgroups confer different cytolytic activities in red blood cells and cardiovascular effects in rats. Conclusion: Diversification within the toxin family may influence toxin function/specificity. Significance: Characterization of the toxins provides new insight into their potential roles in human envenoming.
“…All three schypozoan jellyfishes had rather potent lethal toxicity compared with the two hydrozoans ( Table 1). Crustacean lethal polypeptide toxins isolated from box jellyfishes such as Carybdea rastoni [26], Carybdea alata [32], and Chiropsalmus quadrigatus [33] belong to a novel polypeptide family designated as the box jellyfish toxin family [16] and it may also be the case that a novel polypeptide toxin family could be present in the three coronate scyphozoan medusae. To date, some pharmaceuticals have been developed from marine natural toxins.…”
Section: Discussionmentioning
confidence: 99%
“…Water-soluble extracts obtained from these deep-sea jellyfishes were subjected to (1) cytotoxicity, (2) hemolytic activity and (3) crustacean lethal toxicity tests. The crude extract preparation methods and bioactivity tests adopted in this study have been routinely used in our laboratory for discovering novel bioactive polypeptides from shallow-water cnidarians [15][16][17][18][19].…”
Many polypeptides isolated from shallow water cnidarian species have been utilized as valuable biochemical tools in both basic and applied biological sciences. Deepwater cnidarian species might be another potential resource for novel biochemical tools. However, because of limited access to cnidarian samples from deep-sea environments, bioactive polypeptides have never before been reported from this group. In this study, we collected twelve deep-sea jellyfish species (nine hydrozoans and three scyphozoans) using a plankton net that was specially designed for collecting deep-sea organisms, and prepared water-soluble extracts, presumably containing polypeptides, of these jellyfishes. The extracts were subjected to cytotoxicity, hemolytic activity, and crustacean lethal toxicity tests. In the cytotoxicity test, six out of the nine tested hydrozoan species showed activity. In the hemolytic activity test, only three hydrozoans showed activity and none of the scyphozoan jellyfishes showed activity. In the crustacean lethality test, two hydrozoan jellyfishes and all three of the tested scyphozoan jellyfishes showed lethal activity. These results revealed a high incidence of watersoluble bioactive substances occurring in these deepsea jellyfishes. Furthermore, all the heat-treated and the methanol-treated crude jellyfish extracts lost their bioactivities. Thus, it is likely that the bioactive compounds in the water-soluble extracts were unstable polypeptides (proteins). This is the first published report on bioactivities in extracts from deep-sea jellyfishes.
“…By contrast, Chiropsalmus and Chiropsella species are considered much less dangerous (but see Bengtson et al 1991). Differences in toxicity among chirodropids may be explained by differences in the amount of tentacle surface area, and consequently, the amount of venom that can be delivered (see Nagai 2003). Interestingly, an unvouchered tissue specimen from Palau appears to be closely related to C. yamaguchii from Japan, raising questions about the toxicity and identity of this chirodropid.…”
Section: Discussion (A) Phylogenetic Analyses and Signalmentioning
confidence: 99%
“…Similarly, lethal doses of venom appear much lower in C. brevipedalia when compared with Alatina sp. and C. yamaguchii (Nagai 2003). Note, however, that these haemolytic assays do not appear to have been standardized among treatments, potentially making direct comparisons unreliable.…”
Section: Discussion (A) Phylogenetic Analyses and Signalmentioning
Cubozoa (Cnidaria: Medusozoa) represents a small clade of approximately 50 described species, some of which cause serious human envenomations. Our understanding of the evolutionary history of Cubozoa has been limited by the lack of a sound phylogenetic hypothesis for the group. Here, we present a comprehensive cubozoan phylogeny based on ribosomal genes coding for near-complete nuclear 18S (small subunit) and 28S (large subunit) and partial mitochondrial 16S. We discuss the implications of this phylogeny for our understanding of cubozoan venom evolution, biogeography and life-history evolution. Our phylogenetic hypothesis suggests that: (i) the last common ancestor of Carybdeida probably possessed the mechanism(s) underlying Irukandji syndrome, (ii) deep divergences between Atlantic and Indo-Pacific clades may be explained by ancient vicariant events, and (iii) sexual dimorphism evolved a single time in concert with complex sexual behaviour. Furthermore, several cubozoan taxa are either para-or polyphyletic, and we address some of these taxonomic issues by designating a new family, Carukiidae, a new genus, Copula, and by redefining the families Tamoyidae and Tripedaliidae. Lastly, cubozoan species identities have long been misunderstood and the data presented here support many of the recent scientific descriptions of cubozoan species. However, the results of a phylogeographic analysis of Alatina moseri from Hawai'i and Alatina mordens from Australia indicate that these two nominal species represent a single species that has maintained metapopulation cohesion by natural or anthropogenic dispersal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.